Avacopan
A selective complement C5a receptor antagonist taken by mouth that dampens the inflammatory response driven by the complement system in certain autoimmune vasculitides such as ANCA-associated vasculitis. It allows dose reduction of steroids while maintaining disease control.
Moleküler Ağırlık
581,6000 g/mol
LogP
7,20
TPSA
61,40 Ų
Lipinski RO5
Başarısız
Terapötik Alanlar
Etki Mekanizması
Competitively binds to its target receptor without activating it, blocking the natural ligand from binding and preventing receptor-mediated signaling.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Competitively binds to its target receptor without activating it, blocking the natural ligand from binding and preventing receptor-mediated signaling.
2D Yapı
Cite this structure
Embed this structure
SMILES
Cc1ccc(NC(=O)[C@H]2CCCN(C(=O)c3c(C)cccc3F)[C@H]2c2ccc(NC3CCCC3)cc2)cc1C(F)(F)F
InChI
InChI=1S/C33H35F4N3O2/c1-20-12-15-25(19-27(20)33(35,36)37)39-31(41)26-10-6-18-40(32(42)29-21(2)7-5-11-28(29)34)30(26)22-13-16-24(17-14-22)38-23-8-3-4-9-23/h5,7,11-17,19,23,26,30,38H,3-4,6,8-10,18H2,1-2H3,(H,39,41)/t26-,30-/m0/s1
Molecular Formula
C33H35F4N3O2
HBD / HBA
2 / 7
Döndürülebilir Bağlar
6
Ağır Atomlar
42
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Sıkça Sorulan Sorular
A selective complement C5a receptor antagonist taken by mouth that dampens the inflammatory response driven by the complement system in certain autoimmune vasculitides such as ANCA-associated vasculitis. It allows dose reduction of steroids while maintaining disease control.
Competitively binds to its target receptor without activating it, blocking the natural ligand from binding and preventing receptor-mediated signaling.
Yes, Avacopan is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL3989871. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 49841217. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="avacopan"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/avacopan/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/avacopan/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/avacopan/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="avacopan"></drugfyi-drug>